A high-conviction short opportunity is presented in aTyr Pharma (ATYR), with an expectation of failed Phase 3 data within the next four to six weeks. Conversely, Sarepta Therapeutics (SRPT) is considered a strong buy, as the market has not fully priced in recent positive FDA news. Another key long position is Abivax (ABVX), which is viewed as a potential acquisition target with a possible buyout price of $150 to $170 per share. Finally, a bearish stance is maintained on the quantum computing sector, with active short positions in stocks like D-Wave (QBTS), Rigetti (RGTI), and IonQ (IONQ).

Cardiff Oncology (CRDF)

• The speaker analyzed Cardiff Oncology in real-time ahead of a clinical trial data release, expressing a strong bearish view and establishing a short position.
• His initial thesis was that the company's drug "almost certainly doesn't work" and that the stock would fall from $3 to $1 if the data confirmed this.
• After the data was released, he described it as "incrementally bad data." While not a complete failure, the results were not what bulls were hoping for.
  • The treatment arm's advantage over the control arm narrowed significantly from the previous update. The high dose went from being 31% better to only 16% better than the control.
  • He noted the control group's performance improved while the drug group's performance slightly declined, which he called "the wrong direction."
• He concluded that the data was not good enough for the stock to go up and that it would likely sell off. He decided it was "time to get out of this short," suggesting the conviction for a massive drop had weakened, but the overall outlook remained negative.

Takeaways

• The speaker was short CRDF going into the data release, anticipating a failure.
• The data was viewed as negative but not a "slam dunk loss," leading him to cover his short for a small gain.
• The key takeaway is that the drug's effectiveness is questionable as its lead over the standard of care is shrinking as more patient data comes in. This trend suggests the final data may show no benefit.

aTyr Pharma (ATYR)

• The speaker is extremely bearish on aTyr Pharma, calling it a "fake drug, fake everything."
• He stated his conviction on the short is a 9 or 10 out of 10, making it one of his highest-conviction positions.
• He believes the bull case is "literally impossible" to articulate and that it's "one of the worst drugs I've ever seen."
• He is anticipating Phase 3 data to be released in the next four to six weeks and projects that it will fail.
• He mentions being "all in on ATYR" in terms of his short positions.

Takeaways

• This is a high-conviction short idea from the speaker.
• The primary catalyst is the upcoming Phase 3 data release in 4-6 weeks, which he expects to be negative and cause the stock to drop significantly.
• Investors should be aware of the high-risk, high-reward nature of betting on clinical trial outcomes.

Sarepta Therapeutics (SRPT)

• The speaker is very bullish on Sarepta, believing the stock is significantly undervalued following recent "massive breakthrough" positive news from the FDA.
• He is surprised the stock isn't trading much higher, stating, "I really thought it would double or more."
• He mentioned two price targets during the stream: first $30, and later $50. (Note: This may be a misstatement or reflect a pre-split price, as the stock was trading well above this. The key sentiment is that he sees significant upside).
• He views the investment as having a favorable risk/reward profile, stating you get "none of the risk with... only a little bit less upside" compared to riskier biotech plays.
• He holds SRPT as one of his largest long positions, alongside Abivax.

Takeaways

• The speaker sees SRPT as a strong buy due to positive regulatory developments that he believes the market has not fully priced in.
• He believes the company's "problems are gone" and the stock has potential to appreciate significantly from current levels.

Abivax (ABVX)

• The speaker is very bullish on Abivax and holds it as one of his largest long positions.
• He bought the stock at $52 after positive data was released and noted it was trading at $70 during the stream.
• He believes the company is a potential acquisition target, mentioning that a banker could get it sold for $150 per share and that a price of $170 would be even crazier.
• He noted that ABVX was his second-biggest winning trade in his public portfolio.

Takeaways

• The speaker views ABVX as a strong long position with significant upside, both as a standalone company and as a potential buyout candidate.
• The potential acquisition prices of $150-$170 represent a substantial premium to its current price.

Quantum Computing Stocks (QBTS, RGTI, IONQ)

• The speaker is actively shorting a basket of quantum computing stocks.
• He specifically named D-Wave (QBTS), Rigetti (RGTI), and IonQ (IONQ) as his three biggest losing positions.
• Despite the losses, he remains committed to the short thesis, stating, "I'm not out of my quantum shorts" and "I'm holding the quantum shorts to earnings."

Takeaways

• The speaker is bearish on the quantum computing sector and is maintaining short positions despite them moving against him.
• This is a high-risk, contrarian trade against a sector that has seen investor interest. He is betting that their upcoming earnings will be poor.

Novo Nordisk (NVO)

• The speaker expressed a bearish and confused view on Novo Nordisk, the maker of Ozempic.
• He described the situation as "really bearish for all of pharma and the market" and called the company "trashy."
• He questioned if the company, one of the largest in the world, could be "dead."
• He believes that any major issues for NVO would also be bearish for its main competitor, Eli Lilly (LLY).
• He plans to do more research on a potential short thesis for the company.

Takeaways

• The speaker is exploring a potential large-scale bearish thesis on NVO.
• He suggests that problems with the GLP-1 market leaders could have broad negative implications for the pharmaceutical sector and the market as a whole.

Portfolio & Strategy Insights

• The speaker shared an attribution analysis of his public portfolio, revealing his strategy and performance.
• Biotech Focus: His portfolio is heavily focused on biotech, which has been his primary source of profit. He stated his biotech picks were up +62% while his non-biotech picks were down -46%.
• Long/Short Performance: His long positions have generated +33% returns, while his short positions have cost him -18%. He remains confident his shorts will eventually become profitable.
• Major Winners: His biggest profit came from a short position in Inmune Bio (INMB). Other notable winners include long positions in Abivax (ABVX) and SharpLink Gaming (SBET), and a short on Kohl's (KSS).
• Major Losers: His biggest losses have come from short positions in quantum computing stocks (QBTS, RGTI, IONQ) and other tech/biotech names like Humacyte (HUMA) and Joby (JOBY).

Takeaways

• The speaker's main strategy involves making high-conviction, concentrated bets, primarily in the biotech sector.
• He is not afraid to hold losing short positions if his conviction remains high, as seen with the quantum stocks.
• His success hinges on correctly predicting the outcomes of binary events like clinical trials, as demonstrated by his large wins (INMB) and current major bets (ATYR, SRPT, ABVX).